Logo image of BCDA

BIOCARDIA INC (BCDA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BCDA - US09060U6064 - Common Stock

1.43 USD
+0.06 (+4.38%)
Last: 12/8/2025, 8:00:02 PM
Fundamental Rating

1

BCDA gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. BCDA has a bad profitability rating. Also its financial health evaluation is rather negative. BCDA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BCDA had negative earnings in the past year.
In the past year BCDA has reported a negative cash flow from operations.
In the past 5 years BCDA always reported negative net income.
In the past 5 years BCDA always reported negative operating cash flow.
BCDA Yearly Net Income VS EBIT VS OCF VS FCFBCDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M -15M

1.2 Ratios

BCDA has a Return On Assets of -421.11%. This is amonst the worse of the industry: BCDA underperforms 95.67% of its industry peers.
Industry RankSector Rank
ROA -421.11%
ROE N/A
ROIC N/A
ROA(3y)-240.8%
ROA(5y)-173.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BCDA Yearly ROA, ROE, ROICBCDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BCDA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BCDA Yearly Profit, Operating, Gross MarginsBCDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

1

2. Health

2.1 Basic Checks

BCDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BCDA has been increased compared to 1 year ago.
Compared to 5 years ago, BCDA has less shares outstanding
BCDA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BCDA Yearly Shares OutstandingBCDA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
BCDA Yearly Total Debt VS Total AssetsBCDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

BCDA has an Altman-Z score of -123.61. This is a bad value and indicates that BCDA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -123.61, BCDA is not doing good in the industry: 96.42% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -123.61
ROIC/WACCN/A
WACC8.78%
BCDA Yearly LT Debt VS Equity VS FCFBCDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 0.33 indicates that BCDA may have some problems paying its short term obligations.
BCDA has a worse Current ratio (0.33) than 94.16% of its industry peers.
BCDA has a Quick Ratio of 0.33. This is a bad value and indicates that BCDA is not financially healthy enough and could expect problems in meeting its short term obligations.
BCDA has a worse Quick ratio (0.33) than 93.97% of its industry peers.
Industry RankSector Rank
Current Ratio 0.33
Quick Ratio 0.33
BCDA Yearly Current Assets VS Current LiabilitesBCDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 17.91% over the past year.
Looking at the last year, BCDA shows a very negative growth in Revenue. The Revenue has decreased by -64.67% in the last year.
The Revenue has been decreasing by -5.41% on average over the past years.
EPS 1Y (TTM)17.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.66%
Revenue 1Y (TTM)-64.67%
Revenue growth 3Y47.05%
Revenue growth 5Y-5.41%
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 14.32% on average over the next years. This is quite good.
The Revenue is expected to grow by 70.15% on average over the next years. This is a very strong growth
EPS Next Y61.55%
EPS Next 2Y36.3%
EPS Next 3Y23.83%
EPS Next 5Y14.33%
Revenue Next Year-84.28%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y70.15%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BCDA Yearly Revenue VS EstimatesBCDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2028 2M 4M 6M 8M
BCDA Yearly EPS VS EstimatesBCDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -5 -10 -15 -20 -25

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BCDA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BCDA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCDA Price Earnings VS Forward Price EarningsBCDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCDA Per share dataBCDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1

4.3 Compensation for Growth

BCDA's earnings are expected to grow with 23.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.3%
EPS Next 3Y23.83%

More info and screens

0

5. Dividend

5.1 Amount

BCDA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOCARDIA INC

NASDAQ:BCDA (12/8/2025, 8:00:02 PM)

1.43

+0.06 (+4.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/amc
Earnings (Next)03-24 2026-03-24/amc
Inst Owners4.02%
Inst Owner Change40.33%
Ins Owners17.6%
Ins Owner Change1.38%
Market Cap15.17M
Revenue(TTM)477.00K
Net Income(TTM)-8.80M
Analysts82.5
Price Target15.81 (1005.59%)
Short Float %2.25%
Short Ratio0.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-13.37%
Min EPS beat(2)-48.32%
Max EPS beat(2)21.57%
EPS beat(4)3
Avg EPS beat(4)20.95%
Min EPS beat(4)-48.32%
Max EPS beat(4)60.78%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)158.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-9.52%
EPS NY rev (1m)5.35%
EPS NY rev (3m)-9.52%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-100%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.48
EYN/A
EPS(NY)-1.17
Fwd EYN/A
FCF(TTM)-0.8
FCFYN/A
OCF(TTM)-0.8
OCFYN/A
SpS0
BVpS-0.18
TBVpS-0.18
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -421.11%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-240.8%
ROA(5y)-173.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.91%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.33
Quick Ratio 0.33
Altman-Z -123.61
F-Score2
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)36.91%
Cap/Depr(5y)70.72%
Cap/Sales(3y)6.02%
Cap/Sales(5y)9.96%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.66%
EPS Next Y61.55%
EPS Next 2Y36.3%
EPS Next 3Y23.83%
EPS Next 5Y14.33%
Revenue 1Y (TTM)-64.67%
Revenue growth 3Y47.05%
Revenue growth 5Y-5.41%
Sales Q2Q%N/A
Revenue Next Year-84.28%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y70.15%
EBIT growth 1Y-2.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0.9%
EBIT Next 3Y-11.84%
EBIT Next 5Y-0.64%
FCF growth 1Y21.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.07%
OCF growth 3YN/A
OCF growth 5YN/A

BIOCARDIA INC / BCDA FAQ

Can you provide the ChartMill fundamental rating for BIOCARDIA INC?

ChartMill assigns a fundamental rating of 1 / 10 to BCDA.


What is the valuation status for BCDA stock?

ChartMill assigns a valuation rating of 1 / 10 to BIOCARDIA INC (BCDA). This can be considered as Overvalued.


Can you provide the profitability details for BIOCARDIA INC?

BIOCARDIA INC (BCDA) has a profitability rating of 0 / 10.


How financially healthy is BIOCARDIA INC?

The financial health rating of BIOCARDIA INC (BCDA) is 1 / 10.